Bajaj Finserv Healthcare Fund Regular Plan - Growth
Bajaj Asset Management Limited
₹11.21 (+0.75%)
NAV as of 9 Oct 2026
Minimum Investment: ₹500
Return
15.01% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.38%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹500
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,202
Invested ₹1,000
▲+20.22%1 year
₹1,150
Invested ₹1,000
▲+15.01%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | BSE Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +15.01% | — | — | — |
| Cumulative returns (%) | +15.01% | — | — | — |
Fund Manager
| Manager | Bharat Hegde |
|---|---|
| Role | Manager |
| Manager Tenure | 0.37 yrs |
About Fund
| Date of Incorporation | 27 Dec 2024 |
|---|---|
| Fund House | Bajaj Asset Management Limited |
| Custodian | Deutsche Bank AG |
| Registrar / Transfer Agent | Bajaj Asset Management Limited |
| Address | 1 Great Winchester Street |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Divi's Laboratories Ltd | 10.55% |
| Sun Pharmaceuticals Industries Ltd | 8.21% |
| Rubicon Research Ltd | 6.81% |
| Piramal Pharma Ltd | 6.72% |
| Aurobindo Pharma Ltd | 6.18% |
| Apollo Hospitals Enterprise Ltd | 6.00% |
| Torrent Pharmaceuticals Ltd | 5.03% |
| Neuland Laboratories Ltd | 4.11% |
| Biocon Ltd | 4.00% |
| Emcure Pharmaceuticals Ltd | 3.84% |
| Cipla Ltd | 3.72% |
| Fortis Healthcare Ltd | 3.60% |
| Glenmark Pharmaceuticals Ltd | 3.45% |
| Dr Reddy's Laboratories Ltd | 3.43% |
| Max Healthcare Institute Ltd Ordinary Shares | 3.35% |
| Dr. Lal PathLabs Ltd | 3.34% |
| Syngene International Ltd | 3.25% |
Investment Strategy
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
wealth creation over long term
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.